<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>HTML17 - Product Cards</title>
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css">
  <style>
    body {
      font-family: Arial, sans-serif;
      background: #f4f4f4;
      margin: 0;
      padding: 20px;
    }
    .grid {
      display: grid;
      grid-template-columns: repeat(auto-fill, minmax(250px, 1fr));
      gap: 20px;
    }
    .card {
      background: #fff;
      border-radius: 12px;
      padding: 20px;
      box-shadow: 0 4px 6px rgba(0,0,0,0.1);
      transition: transform 0.2s;
    }
    .card:hover {
      transform: translateY(-5px);
    }
    .icon {
      font-size: 30px;
      margin-bottom: 10px;
      color: #0077b6;
    }
    .name {
      font-size: 18px;
      font-weight: bold;
      margin-bottom: 8px;
    }
    .indication {
      font-size: 14px;
      color: #555;
      margin-bottom: 10px;
    }
    .details {
      font-size: 13px;
      color: #777;
    }
  </style>
</head>
<body>
  <h2>HTML17 - Product Cards</h2>
  <div class="grid">

    <div class="card">
      <div class="icon"><i class="fa-solid fa-dna"></i></div>
      <div class="name">Capecitabine (Xeloda)</div>
      <div class="indication">Breast & colorectal cancer.</div>
      <div class="details">Oral chemotherapy. Widely prescribed.</div>
    </div>

    <div class="card">
      <div class="icon"><i class="fa-solid fa-pills"></i></div>
      <div class="name">Enzalutamide (Xtandi)</div>
      <div class="indication">Prostate cancer.</div>
      <div class="details">Androgen receptor inhibitor. Improves survival.</div>
    </div>

    <div class="card">
      <div class="icon"><i class="fa-solid fa-vial"></i></div>
      <div class="name">Palbociclib (Ibrance)</div>
      <div class="indication">Breast cancer.</div>
      <div class="details">CDK4/6 inhibitor. Used with endocrine therapy.</div>
    </div>

    <div class="card">
      <div class="icon"><i class="fa-solid fa-syringe"></i></div>
      <div class="name">Nivolumab (Opdivo)</div>
      <div class="indication">Multiple cancers (melanoma, lung, etc.).</div>
      <div class="details">Immune checkpoint inhibitor. Improves long-term survival.</div>
    </div>

    <div class="card">
      <div class="icon"><i class="fa-solid fa-heart-pulse"></i></div>
      <div class="name">Dabrafenib (Tafinlar)</div>
      <div class="indication">BRAF-mutant melanoma.</div>
      <div class="details">Often combined with MEK inhibitors.</div>
    </div>

    <div class="card">
      <div class="icon"><i class="fa-solid fa-dna"></i></div>
      <div class="name">Osimertinib (Tagrisso)</div>
      <div class="indication">EGFR-mutant lung cancer.</div>
      <div class="details">Targeted therapy. Strong progression-free survival benefit.</div>
    </div>

    <div class="card">
      <div class="icon"><i class="fa-solid fa-vial"></i></div>
      <div class="name">Erlotinib (Tarceva)</div>
      <div class="indication">Non-small cell lung cancer.</div>
      <div class="details">EGFR inhibitor. Oral targeted therapy.</div>
    </div>

    <div class="card">
      <div class="icon"><i class="fa-solid fa-pills"></i></div>
      <div class="name">Imatinib (Gleevec)</div>
      <div class="indication">CML, GIST.</div>
      <div class="details">Revolutionary targeted therapy. First-in-class tyrosine kinase inhibitor.</div>
    </div>

    <div class="card">
      <div class="icon"><i class="fa-solid fa-dna"></i></div>
      <div class="name">Dasatinib (Sprycel)</div>
      <div class="indication">Leukemia (CML, ALL).</div>
      <div class="details">Potent BCR-ABL inhibitor. Used after imatinib resistance.</div>
    </div>

    <div class="card">
      <div class="icon"><i class="fa-solid fa-vial"></i></div>
      <div class="name">Nilotinib (Tasigna)</div>
      <div class="indication">Chronic myeloid leukemia.</div>
      <div class="details">Second-generation tyrosine kinase inhibitor.</div>
    </div>

  </div>
</body>
</html>
